Anaplastic malignant neoplastic disease enzyme (ALK)-positive non-small cell respiratory organ cancers (NSCLC) account for three-dimensional to seven-membered of all NSCLC and need a typical treatment by crizotinib. However, crizotinib resistance is frequent at intervals the primary twelve months of treatment. Ceritinib may be a novel amino acid enzyme matter of ALK recently introduced in France for pathological process or regionally advanced crizotinib-resistant ALK NSCLC. we have a tendency to report the primary use of ceritinib in our establishment with a spectacular tumoral response once solely three months of treatment. This case demonstrates the main role of F-FDG PET/CT for watching the effectiveness of this new treatment.